(1 - 25 von 29
)
Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business...
www.finanznachrichten.de
Origenis GmbH, a German biotech company specializing in the discovery and development of highly selective small molecule kinase inhibitors for CNS disorders,...
Origenis announces patent grants for lead small molecule LRRK2...
www.bionity.com
Origenis GmbH announced that the US Patent Office has granted the company two important patents, US9,499,535 and US9,637,491, that protect the further...
Eine KI-basierte Wirkstoffplattform sorgt für Furore -
www.goingpublic.de
Case Study Origenis GmbH: Mit Small Molecules gegen neurodegenerative Erkrankungen
Origenis GmbH Announces Global License and Collaboration Agreement...
- Companies Initiate Lead Optimization Program Leveraging theOrigenis AI Discovery Platform to Identify RNA-targeted Small Molecule Compounds for Development...
sortiert nach Relevanz / Datum